Chronic Pain SyndromeNCT03445403
Offset Analgesia as a Measure of Central Sensitization in Children
A study testing Offset analgesia in people with Chronic Pain Syndrome and Chronic Daily Headache, run by Boston Children's Hospital at 1 site in United States.
Trial summary
Pediatric chronic pain disorders are common and consequential in Western societies, occurring in 25-80% of population-based samples with a median prevalence of 11-38% and significant pain-related disability in 3-5% of these children. Read more about this study
- Who is it for?
- Ages 10 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Pain Syndrome, Chronic Daily Headache, Functional Abdominal Pain Syndrome
- What is being tested?
- Offset analgesia
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2018to 1 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Patients experiencing chronic pain defined as pain persisting for 3 months.
- Ages 10-17 years, both sexes and all races and ethnic groups.
- Patients with moderate pain rated as 5/10 and greater on a numeric rating scale of 0 to 10 points.
- English speaking.
- If patients are taking medications such as psychotropic (e.g., SSRI), opioid, anxiolytics or anticonvulsive drugs for pain such as gabapentinoids, they must be on stable doses for at least one week.
- Stable anxiety and depression.
Who cannot join
- Intermittent pain or pain of less than 3-month duration.
- Allodynia in the upper extremities
- Patients with poor understanding of English language or developmental disorders that affect the ability to reliably rate pain, read questionnaires and follow study instructions.
- Children and adolescents with a history of central nervous system, heart, kidney, liver, and respiratory system diseases.
- Psychiatric disorders such as conversion, bipolar disorder or psychosis.
Trial locations and contacts
1 site in 1 country.
United States1 site
Boston Children's Hospital
Waltham, Massachusetts, 02453
About this study
Official title: Offset Analgesia as a Measure of Central Sensitization in Children With Chronic Pain Disorders
Pediatric chronic pain disorders are common and consequential in Western societies, occurring in 25-80% of population-based samples with a median prevalence of 11-38% and significant pain-related disability in 3-5% of these children. Pediatric chronic pain disorders have a negative impact on many aspects children's lives including mobility, night sleep, school attendance, peer relationships, family functioning, and overall quality of life. Parents caring for these children risk loss of parental earnings, and these disorders place a high financial burden on healthcare. In a nationally representative sample in the United States, costs related to health care were significantly higher ($1,339 per capita) for children with chronic pain disorders compared to children with common pediatric health conditions of ADHD, asthma and obesity.
In children with clinical chronic pain conditions, such as daily headaches or fibromyalgia, chronic pain is presumably a persistent state of an overly excitable nervous system. This phenomenon known as central sensitization is characterized by excessive pain sensitivity that occurs in response to non-painful stimuli, such as light touch or contact with clothing, and slightly painful stimuli, such as a light pinprick. This hypersensitivity results from peculiar changes in the working of the central nervous system, including the spinal cord and brain, and leads to unusual intensification of pain that is out of proportion to the inciting stimulus. For example, light touch from clothing on the skin is perceived as intensely painful. Central sensitization is also thought to contribute to the spreading of pain to other body sites in several chronic pain disorders.
Read more
In chronic pain disorders, the function of the central descending inhibitory modulating system is likely impaired and is traditionally measured by a phenomenon identified as "conditioned pain modulation (CPM)" and more recently measured by a phenomenon of "offset analgesia" (OA). The OA test is more robust than the CPM test and likely more acceptable to most patients, especially children, because it is shorter in duration and uses a more tolerable painful stimulus. Compared to CPM, the OA test is more tolerable because it is conducted using a painful test stimulus that is less than the maximal (suprathreshold). Additionally, the time of exposure to the painful stimulus is significantly shorter, a few seconds, in the OA test compared to CPM.
The central descending inhibitory pathway that modulates pain as tested by OA is functional and mature in healthy children as young as 6 year of age, but it has yet to be investigated in children with chronic pain disorders. The investigators plan to test OA responses in a population of common pediatric pain disorders with overlapping symptomology attributed to central sensitization (such as chronic musculoskeletal pain, chronic abdominal pain and chronic headaches and chronic regional pain syndromes) and compare their responses with an age- and sex-matched control group. The characteristics of OA responses in each group will allow for assessment of the presence or absence of central sensitization as a mechanism driving the persistent, abnormal pain in a subgroup of these chronic pain disorders. The investigators hypothesize that central sensitization is the potential contributory mechanism of the central nervous system heightened sensitivity to two testing stimuli of painful (moderate heat discomfort sensation) and non-painful (warmth sensation) in children with chronic pain disorders. These types of sensations mimic those that children would be expected to experience their natural environment during typical activities of daily living such as showering/bathing in warm water or hand washing.
Additionally, the Pain Sensitivity Questionnaire (PSQ) and Central Sensitization Inventory (CSI) will be used as clinical screening tools for subjective report of sensitization symptoms, and are simple and easy to administer in a clinical setting. The investigators hypothesize that these measures will correlate with the objective offset analgesia responses thus allowing for assessment of central sensitization in children with chronic pain disorders.
These tests are advantageous because they are feasible to perform rapidly in a clinic setting and have utility for measurement of patient responses to therapeutic interventions. If this concept is supported by this study, future studies could utilize OA to examine the effects of various pharmacological and physical interventions used to manage children with chronic pain disorders including intensive interdisciplinary rehabilitation or specific interventions such as aerobic exercise, which likely modulates pain via similar mechanisms.
Read the detailed description
Specific Aims/Objectives To date, OA has not been evaluated in pediatric chronic pain disorders. In the current study, the investigators plan to measure OA responses in a population of common pediatric pain disorders. The primary objective of this study is to determine if OA paradigm can detect impairment of central inhibitory modulation pathways in subgroups of chronic pain disorders in children and adolescents. The investigators hypothesize that chronic pain in children and adolescents results from central sensitization and impaired central inhibitory modulation of pain and thus children with chronic pain disorders will have a decreased OA response compared with healthy controls. If the results of this study are positive, this testing paradigm could be a valuable objective marker in examining the efficacy of pharmacological and/or rehabilitative treatment modalities in reversing or alleviating central sensitization-induced pain in children with chronic pain disorders. Additionally, if existing self-report questionnaires, Pain Sensitivity Questionnaire (PSQ) and Central Sensitivity Inventory, correlate with the magnitude of offset analgesia observed, they could be used to screen for central sensitization in high volume and busy clinical settings.
Aim 1: To determine if children with common chronic pain disorders, including musculoskeletal pain, complex regional pain syndrome, functional abdominal pain and chronic headaches demonstrate impaired ability to actuate central descending inhibitory function as measured by a test of offset analgesia.
To accomplish this aim, the investigators will compare 30 children with common chronic pain disorders with 30 age and sex matched controls. Power will be 80% to detect a 20% or larger difference in the change in self-reported pain scores as a result of the dynamic heat pain test stimulus between the two groups using a Student t-test (nQuery Advisor version 7.0, Statistical Solutions, Cork, Ireland).
Aim 2: To determine if the Pain Sensitivity Questionnaire (PSQ) and/or Central Sensitization Inventory (CSI) can serve as screening tools for assessment of central sensitization i.e., impairment of central descending inhibitory function in children with common chronic pain disorders.
To accomplish this aim investigators will correlate scores on the above scales with the magnitude of offset analgesia using Pearson correlations in 30 children with chronic pain disorders and 30 healthy age and sex-matched controls. The investigators hypothesize that the magnitude of OA will correlate with either PSQ, CSI or both thus these questionnaires would serve as assessment tools for central sensitization in children with common chronic pain disorders in clinical setting. The Mann-Whitney U-test will be applied to compare medians and interquartile ranges on the PSQ and CSI between the chronic pain and healthy control groups. In addition, investigators will identify individuals who show a decrease in VAS pain scores after the dynamic test stimulus of at least 20% (responders) and will assess whether PSQ and CSI can predict responders and non-responders using a receiver operating characteristic (ROC) curve approach with area under the curve (AUC) to measure how well pain perception and central sensitization assessment tools can help to identify responders and non-responders.
- Conditions
- Chronic Pain Syndrome, Chronic Daily Headache, Functional Abdominal Pain Syndrome, Musculoskeletal Pain Disorder, CRPS (Complex Regional Pain Syndromes)
- Being tested
- Offset analgesia
- Keywords
- Offset analgesia, Quantitive sensory testing
- Medical subject headings
- Headache Disorders, Collagen Diseases, Complex Regional Pain Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Offset analgesiaOther
Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
| Study group | Role | What they receive |
|---|---|---|
| Chronic pain disorders | Experimental | Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm. Receives: Other: Offset analgesia |
| Healthy controls | Active comparator | Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm. Receives: Other: Offset analgesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Response to Offset analgesia stimulus
A reduction in self-reported pain intensity when a moderate heat-pain stimulus is applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds. During all tests, patients will rate heat pain intensity continuously in real time using the linear, electronic visual analogue scale (eVAS). Patients will use their dominant hand to operate sliding knob of the eVAS with the following two anchors on 0 to 100 mm line. The left endpoint designated as "no pain sensation" (0 mm) and the right endpoint as "most intense pain sensation imaginable" (100 mm).
Measured: outcome will be observed in a single session over one hour period
Secondary outcomes (4)
Response to a Controlled Stimulus
A reduction in self-reported pain intensity when a moderate heat-pain stimulus is applied for 5 seconds, raised by 1 degree C for 5 second, reduced to 32 degree C, and held for 20 seconds. During all tests, patients will rate heat pain intensity continuously in real time using the linear, electronic visual analogue scale (eVAS). Patients will use their dominant hand to operate sliding knob of the eVAS with the following two anchors on 0 to 100 mm line. The left endpoint designated as "no pain sensation" (0 mm) and the right endpoint as "most intense pain sensation imaginable" (100 mm).
Measured: outcome will be observed in a single session over one hour period
Response to a Constant Stimulus
A reduction in self-reported pain intensity when a moderate heat-pain stimulus (test temperature) is applied 30 seconds. During all tests, patients will rate heat pain intensity continuously in real time using the linear, electronic visual analogue scale (eVAS). Patients will use their dominant hand to operate sliding knob of the eVAS with the following two anchors on 0 to 100 mm line. The left endpoint designated as "no pain sensation" (0 mm) and the right endpoint as "most intense pain sensation imaginable" (100 mm).
Measured: outcome will be observed in a single session over one hour period
Pain sensitivity questionnaire
Self reported pain intensity of imagined painful events in their daily activities. Participants are instructed to rate how painful each situation would be for them on a numeric rating scale ranging from 0 ( = not painful at all) to 10 ( = worst pain imaginable). The total score is derived as an average of sum of each response with higher scores indicating higher pain sensitivity.
Measured: outcome will be observed in a single session over one hour period
Central sensitization inventory
Self reported instrument for screening possible presence of central sensitization. Responses are recorded for the frequency of each symptom on a Likert scale from 0 (never) to 4 (always), resulting in a total possible score of 100. Higher scores are associated with a higher degree of self-reported symptomology.
Measured: outcome will be observed in a single session over one hour period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2018
- Study start1 Apr 2018
- Primary completion27 Dec 2019
- Study completion1 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Pain SyndromeStudies of the same condition, open and under way.
- More trials run by Boston Children's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Response to a moderate heat pain \[defined as a heat stimulus producing pain rated at 50mm on a scale of 0-100 mm\] applied the the skin of the forearm using a paradigm known as offset analgesia will be compared in children with chronic pain disorders and healthy, age and sex matched controls.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Navil Sethna, Boston Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03445403
- Sponsor's protocol ID
- P00025596
- Status last verified
- Feb 2021
- First submitted
- 5 Feb 2018
- Last updated
- 21 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Offset Analgesia as a Measure of Central Sensitization in Children With Chronic Pain Disorders
- ClinicalTrials.gov ID
- NCT03445403
- Acronym / sponsor ID
- P00025596
- Conditions
- Chronic Pain Syndrome, Chronic Daily Headache, Functional Abdominal Pain Syndrome, Musculoskeletal Pain Disorder, CRPS (Complex Regional Pain Syndromes)
- Keywords
- Offset analgesia, Quantitive sensory testing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Boston Children's HospitalUniversity, hospital or other
- Study start
- 1 Apr 2018 (actual)
- Primary completion
- 27 Dec 2019 (actual)
- Study completion
- 1 Dec 2020 (actual)
- First posted
- 26 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pediatric chronic pain disorders are common and consequential in Western societies, occurring in 25-80% of population-based samples with a median prevalence of 11-38% and significant pain-related disability in 3-5% of these children. Pediatric chronic pain disorders have a negative impact on many aspects children's lives including mobility, night sleep, school attendance, peer relationships, family functioning, and overall quality of life. Parents caring for these children risk loss of parental earnings, and these disorders place a high financial burden on healthcare. In a nationally representative sample in the United States, costs related to health care were significantly higher ($1,339 per capita) for children with chronic pain disorders compared to children with common pediatric health conditions of ADHD, asthma and obesity.
In children with clinical chronic pain conditions, such as daily headaches or fibromyalgia, chronic pain is presumably a persistent state of an overly excitable nervous system. This phenomenon known as central sensitization is characterized by excessive pain sensitivity that occurs in response to non-painful stimuli, such as light touch or contact with clothing, and slightly painful stimuli, such as a light pinprick. This hypersensitivity results from peculiar changes in the working of the central nervous system, including the spinal cord and brain, and leads to unusual intensification of pain that is out of proportion to the inciting stimulus. For example, light touch from clothing on the skin is perceived as intensely painful. Central sensitization is also thought to contribute to the spreading of pain to other body sites in several chronic pain disorders.
In chronic pain disorders, the function of the central descending inhibitory modulating system is likely impaired and is traditionally measured by a phenomenon identified as "conditioned pain modulation (CPM)" and more recently measured by a phenomenon of "offset analgesia" (OA). The OA test is more robust than the CPM test and likely more acceptable to most patients, especially children, because it is shorter in duration and uses a more tolerable painful stimulus. Compared to CPM, the OA test is more tolerable because it is conducted using a painful test stimulus that is less than the maximal (suprathreshold). Additionally, the time of exposure to the painful stimulus is significantly shorter, a few seconds, in the OA test compared to CPM.
The central descending inhibitory pathway that modulates pain as tested by OA is functional and mature in healthy children as young as 6 year of age, but it has yet to be investigated in children with chronic pain disorders. The investigators plan to test OA responses in a population of common pediatric pain disorders with overlapping symptomology attributed to central sensitization (such as chronic musculoskeletal pain, chronic abdominal pain and chronic headaches and chronic regional pain syndromes) and compare their responses with an age- and sex-matched control group. The characteristics of OA responses in each group will allow for assessment of the presence or absence of central sensitization as a mechanism driving the persistent, abnormal pain in a subgroup of these chronic pain disorders. The investigators hypothesize that central sensitization is the potential contributory mechanism of the central nervous system heightened sensitivity to two testing stimuli of painful (moderate heat discomfort sensation) and non-painful (warmth sensation) in children with chronic pain disorders. These types of sensations mimic those that children would be expected to experience their natural environment during typical activities of daily living such as showering/bathing in warm water or hand washing.
Additionally, the Pain Sensitivity Questionnaire (PSQ) and Central Sensitization Inventory (CSI) will be used as clinical screening tools for subjective report of sensitization symptoms, and are simple and easy to administer in a clinical setting. The investigators hypothesize that these measures will correlate with the objective offset analgesia responses thus allowing for assessment of central sensitization in children with chronic pain disorders.
These tests are advantageous because they are feasible to perform rapidly in a clinic setting and have utility for measurement of patient responses to therapeutic interventions. If this concept is supported by this study, future studies could utilize OA to examine the effects of various pharmacological and physical interventions used to manage children with chronic pain disorders including intensive interdisciplinary rehabilitation or specific interventions such as aerobic exercise, which likely modulates pain via similar mechanisms.
Detailed description
Specific Aims/Objectives To date, OA has not been evaluated in pediatric chronic pain disorders. In the current study, the investigators plan to measure OA responses in a population of common pediatric pain disorders. The primary objective of this study is to determine if OA paradigm can detect impairment of central inhibitory modulation pathways in subgroups of chronic pain disorders in children and adolescents. The investigators hypothesize that chronic pain in children and adolescents results from central sensitization and impaired central inhibitory modulation of pain and thus children with chronic pain disorders will have a decreased OA response compared with healthy controls. If the results of this study are positive, this testing paradigm could be a valuable objective marker in examining the efficacy of pharmacological and/or rehabilitative treatment modalities in reversing or alleviating central sensitization-induced pain in children with chronic pain disorders. Additionally, if existing self-report questionnaires, Pain Sensitivity Questionnaire (PSQ) and Central Sensitivity Inventory, correlate with the magnitude of offset analgesia observed, they could be used to screen for central sensitization in high volume and busy clinical settings.
Aim 1: To determine if children with common chronic pain disorders, including musculoskeletal pain, complex regional pain syndrome, functional abdominal pain and chronic headaches demonstrate impaired ability to actuate central descending inhibitory function as measured by a test of offset analgesia.
To accomplish this aim, the investigators will compare 30 children with common chronic pain disorders with 30 age and sex matched controls. Power will be 80% to detect a 20% or larger difference in the change in self-reported pain scores as a result of the dynamic heat pain test stimulus between the two groups using a Student t-test (nQuery Advisor version 7.0, Statistical Solutions, Cork, Ireland).
Aim 2: To determine if the Pain Sensitivity Questionnaire (PSQ) and/or Central Sensitization Inventory (CSI) can serve as screening tools for assessment of central sensitization i.e., impairment of central descending inhibitory function in children with common chronic pain disorders.
To accomplish this aim investigators will correlate scores on the above scales with the magnitude of offset analgesia using Pearson correlations in 30 children with chronic pain disorders and 30 healthy age and sex-matched controls. The investigators hypothesize that the magnitude of OA will correlate with either PSQ, CSI or both thus these questionnaires would serve as assessment tools for central sensitization in children with common chronic pain disorders in clinical setting. The Mann-Whitney U-test will be applied to compare medians and interquartile ranges on the PSQ and CSI between the chronic pain and healthy control groups. In addition, investigators will identify individuals who show a decrease in VAS pain scores after the dynamic test stimulus of at least 20% (responders) and will assess whether PSQ and CSI can predict responders and non-responders using a receiver operating characteristic (ROC) curve approach with area under the curve (AUC) to measure how well pain perception and central sensitization assessment tools can help to identify responders and non-responders.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Response to a moderate heat pain [defined as a heat stimulus producing pain rated at 50mm on a scale of 0-100 mm] applied the the skin of the forearm using a paradigm known as offset analgesia will be compared in children with chronic pain disorders and healthy, age and sex matched controls.
| Arm | Type | Receives |
|---|---|---|
| Chronic pain disorders | Experimental | Other: Offset analgesiaAdministration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm. |
| Healthy controls | Active comparator | Other: Offset analgesiaAdministration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm. |
Who may qualify
- Ages
- 10 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (6 listed)
- Patients experiencing chronic pain defined as pain persisting for 3 months.
- Ages 10-17 years, both sexes and all races and ethnic groups.
- Patients with moderate pain rated as 5/10 and greater on a numeric rating scale of 0 to 10 points.
- English speaking.
- If patients are taking medications such as psychotropic (e.g., SSRI), opioid, anxiolytics or anticonvulsive drugs for pain such as gabapentinoids, they must be on stable doses for at least one week.
Key exclusion criteria (5 listed)
- Intermittent pain or pain of less than 3-month duration.
- Allodynia in the upper extremities
- Patients with poor understanding of English language or developmental disorders that affect the ability to reliably rate pain, read questionnaires and follow study instructions.
- Children and adolescents with a history of central nervous system, heart, kidney, liver, and respiratory system diseases.
- Psychiatric disorders such as conversion, bipolar disorder or psychosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Offset analgesiaExposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation. | Other | Chronic pain disorders, Healthy controls |
Primary outcome
Response to Offset analgesia stimulus
Time frame: outcome will be observed in a single session over one hour period
A reduction in self-reported pain intensity when a moderate heat-pain stimulus is applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds. During all tests, patients will rate heat pain intensity continuously in real time using the linear, electronic visual analogue scale (eVAS). Patients will use their dominant hand to operate sliding knob of the eVAS with the following two anchors on 0 to 100 mm line. The left endpoint designated as "no pain sensation" (0 mm) and the right endpoint as "most intense pain sensation imaginable" (100 mm).
4 secondary outcomes
Response to a Controlled Stimulus
Time frame: outcome will be observed in a single session over one hour period
Response to a Constant Stimulus
Time frame: outcome will be observed in a single session over one hour period
Pain sensitivity questionnaire
Time frame: outcome will be observed in a single session over one hour period
Central sensitization inventory
Time frame: outcome will be observed in a single session over one hour period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2021.
- Individual participant dataSharing planned: No
Related trials for Chronic Pain Syndrome
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
Not yet recruitingPhase 1
Simultaneous Engagement of Networks for Alleviating Pain (SENAP)
Neuropathic Pain, Postherpetic Neuralgia
Active, not recruiting
Multimodal Manual Therapy vs. Maitland Mobilization for Chronic Non-Specific Neck Pain
Chronic Neck Pain
Not yet recruiting
Focused Ultrasound Neuromodulation for Chronic Pain
Chronic Pain, Sickle Cell Disease
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Offset analgesia in people with Chronic Pain Syndrome and Chronic Daily Headache, run by Boston Children's Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Response to Offset analgesia stimulus (time frame: outcome will be observed in a single session over one hour period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2021.